Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
168 hedge funds and large institutions have $2.09B invested in Akero Therapeutics in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 50 increasing their positions, 57 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
24% more capital invested
Capital invested by funds: $1.68B → $2.09B (+$410M)
10% more funds holding
Funds holding: 153 → 168 (+15)
1.3% more ownership
Funds ownership: 103.85% → 105.14% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 57
54% less call options, than puts
Call options by funds: $8.49M | Put options by funds: $18.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18M |
| 4 |
RI
RTW Investments
New York
|
+$12.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$5.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$25.4M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$17.6M |
| 3 |
Morgan Stanley
New York
|
-$13M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.81M |
AKRO Hedge Fund Activity: Q3 2024 in Review
168 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2024, worth a combined $2.09B — up 24% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AKRO positions and 16 closed out — a net gain of 15 holders — while 50 added to existing stakes and 57 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $72.5M. The largest seller was Braidwell, exiting entirely with an estimated $25.4M sold.
- 168 institutional investors held Akero Therapeutics (AKRO) as of Q3 2024, up from 153 in Q2 2024.
- Funds reported $2.09B of Akero Therapeutics stock for Q3 2024, up 24% quarter-over-quarter.
- 31 funds opened new Akero Therapeutics positions in Q3 2024 and 16 closed out, a net change of +15 holders.
- The largest Akero Therapeutics buyer in Q3 2024 was Wellington Management Group, an estimated $72.5M added.
- The largest Akero Therapeutics seller in Q3 2024 was Braidwell, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2024.